IJR News - today's news from every side
block
verse
w
o
rdys
billionaire
.ai
your
list
Whiteboard
App
quizie
un
school
New Journal
Loading
Genius — OpenServe
News
Home
Popular
Congress
Genius — OpenServe
Trending
GSK pays Hutchmed $110M upfront in deal worth up to $1.3B
GSK
— Sep 3, 2026
GSK agreed to license Hutchmed’s HMPL-A830, a KRAS-EGFR antibody-drug conjugate, for up to $1.295 billion including $110 million upfront, with global rights outside Mainland China, Hong Kong, Macau and Taiwan while Hutchmed retains development and commercialization duties in those regions. The collaboration targets initial trials in colorectal, pancreatic, and lung cancers, leveraging a dual KRAS-EGFR mechanism to improve efficacy and tolerability.
+13
+2
1
Share
Jared Kim
Dual-targeting KRAS-EGFR is an interesting bet, hope it actually improves tolerability and not just adds complexity.